Related Experiment Video
Updated: Apr 19, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.8K
[Rivaroxaban in non valvular atrial fibrillation: subgroups analysis]
Summary
Rivaroxaban shows efficacy and safety across diverse patient groups, including those with moderate renal failure, heart failure, and diabetes. Analysis also covers cardioversion and myocardial infarction risk in various clinical scenarios.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Context:
- Subgroup analyses from the ROCKET AF study provide deeper insights into rivaroxaban's real-world performance.
- Existing research highlights the need for tailored evaluations of anticoagulants in specific patient populations.
- The X-VeRT trial offers novel data on electrical cardioversion with novel oral anticoagulants.
Purpose:
- To present subgroup analyses of rivaroxaban's efficacy and safety in patients with moderate renal failure, heart failure, and diabetes.
- To analyze post hoc data from the ROCKET AF study on cardioversion procedures.
- To examine the results of the X-VeRT trial, a randomized study on electrical cardioversion with novel oral anticoagulants.
- To conduct a meta-analysis of rivaroxaban studies concerning myocardial infarction risk.
Summary:
- Presents subgroup analyses of rivaroxaban in patients with moderate renal failure, heart failure, and diabetes.
- Includes data on electrical and pharmacological cardioversion from the ROCKET AF study and the X-VeRT trial.
- Evaluates the risk of myocardial infarction across multiple studies involving rivaroxaban for various indications.
Impact:
- Provides comprehensive data to support evidence-based clinical decisions regarding rivaroxaban use.
- Enhances understanding of rivaroxaban's safety and efficacy profile in specific, high-risk patient subgroups.
- Contributes to the ongoing evaluation of novel oral anticoagulants in cardiovascular disease management.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.4K
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
2.3K
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
01:30Acute Coronary Syndrome III: Diagnostic Studies
484
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
484
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
475
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
475
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.7K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.7K